StanleyJordanMD

Nephrology • Los Angeles, CA

Glomerular Disease, Kidney & Pancreas Transplantation

Professor of Pediatrics & Medicine, UCLA

Join to view full profile

Dr. Jordan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jordan's full profile

Already have an account?

Office
8700 Beverly BLD
Los Angeles, CA 90048
Phone+1 310-423-2641

Fax+1 310-967-1800

Summary

Dr. Stanley Jordan is a nephrologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Cedars-Sinai Medical Center and Ronald Reagan UCLA Medical Center. He received his medical degree from University of North Carolina at Chapel Hill School of Medicine and has been in practice 44 years. He specializes in glomerular disease and kidney & pancreas transplantation and is experienced in transplant nephrology, glomerular disease, anti-glomerular basement membrane disease, focal segmental glomerulosclerosis, and membranous glomerulonephritis.

Education & Training

Children's Hospital Los AngelesFellowship, Pediatric Nephrology, 1978 - 1979
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Nephrology, 1976 - 1977
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1973 - 1976
University of North Carolina at Chapel Hill School of MedicineClass of 1973

Certifications & Licensure

CA State Medical License 1974 - 2025
NC State Medical License 1973 - 1998
American Board of Pediatrics Pediatrics
American Board of Pediatrics Diagnostic Laboratory Immunology
American Board of Pediatrics Pediatric Nephrology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2004-2014
Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation Start of enrollment: 2005 Sep 01
Completed
Phase 1, Phase 2
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection Start of enrollment: 2011 Aug 01
Completed
Phase 1, Phase 2
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation Start of enrollment: 2013 Sep 01
Completed
Phase 1, Phase 2
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Start of enrollment: 2014 Sep 01
Completed
Phase 1, Phase 2
A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test Start of enrollment: 2016 Jun 01
Completed
Phase 2
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant Start of enrollment: 2018 Feb 21
Completed
Phase 1, Phase 2
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Start of enrollment: 2018 Feb 27
Active, not recruiting
Phase 1, Phase 2
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation Start of enrollment: 2018 Jun 27
Completed
Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19) Start of enrollment: 2020 Apr 28
Completed
Phase 2
Berinert (C1INH) vs Placebo for DGF/IRI Start of enrollment: 2021 Mar 03
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Competing and Noncompeting Risk Models for Predicting Kidney Allograft Failure.
Agathe Truchot, Marc Raynaud, Ilkka Helanterä, Olivier Aubert, Nassim Kamar
Journal of the American Society of Nephrology. 2024-10-16
9 citations
Cell-free DNA for the detection of kidney allograft rejection.
Olivier Aubert, Cindy Ursule-Dufait, Romain Brousse, Juliette Gueguen, Maud Racapé
Nature Medicine. 2024-08-01
10 citations
Translating B cell immunology to the treatment of antibody-mediated allograft rejection.
Peter S Heeger, Maria Carrera Haro, Stanley Jordan
Nature Reviews. Nephrology. 2024-04-01

Press Mentions

Clinical Trial Highlights Efficacy of Imlifidase for Kidney Transplant RecipientsOctober 26th, 2024
Cedars-Sinai Performs a Record-Setting Number of Solid Organ Transplants in 2022April 25th, 2023
Tipsheet: Cedars-Sinai Clinicians and Investigators Present Research at American Transplant CongressJune 3rd, 2022
Join now to see all